Changes in US stocks | BeiGene (ONC.US) rose more than 6% before the market, net profit for the first three quarters increased 431.8% year on year

The Zhitong Finance App learned that on Thursday, BeiGene (ONC.US) rose more than 6% in the premarket to $402.98. According to financial reports, BeiGene achieved total operating revenue of 34.993 billion yuan in the first three quarters, up 26.8% year on year; net profit to mother was 6.055 billion yuan, up 431.8% year on year. Looking at a single quarter, the company achieved total revenue of 12.774 billion yuan in the third quarter, up 26.8% year on year; net profit to mother was 2,785 billion yuan, up 304.3% year on year.

In the third quarter of 2026, the company's product revenue was 12.560 billion yuan, and product revenue for the same period last year was 9,954 billion yuan. The increase in product revenue was mainly due to the increase in sales of self-developed products Baiyuze® (zebutinib capsules) and Baizean® (tiralizumab injections) and authorized Amgen products.

BeiGene further raised its annual guidance: The company expects revenue for 2026 to be between 46.3 billion yuan and 47 billion yuan, up from the previous forecast of 44.9 billion yuan to 46.2 billion yuan.